BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") delivers results significantly ahead of expectations for its 2020 launch of the VINIA® B2C E-Commerce Business in Israel. Total October 2020 E-Commerce sales (US$ 40,000) were up 3.8X from average sales per month for YTD September 2020 and November 2020 Month to Date Sales (US$ 55,000) is on track to have a 7X increase from the Year-to-Date September 2020 average sales per month.

Along with the revenue increase, there has been a 3X increase in customer count in October 2020 which is expected to increase to 7X in November 2020 compared to the YTD August 2020 monthly average. This increase is attributed to the acquisition of new customers which constitute 75% of the total customer base during the month of November 2020 to date. Further analysis of the results indicates strong purchase fundamentals of the VINIA® brand. The average revenue per transaction has increased by 29% and is now at US$189, with new customers having an initial purchase value of US$174. These results are being achieved at a Cost of Acquisition (media spending) at less than 25% of the First Time Order Value of each customer. This translates into a significant gross profit margin and positive "unit economics" on the B2C E-Commerce sales of VINIA®.

The results described above are significant when using them as a predictor of the performance we expect to achieve in the US with the launch of VINIA® at the end of Q1 2021. With the US population close to 40X the size of Israel's and with a higher percentage of the US population above the age of 45, our core target, the Company is looking forward to entering the US market by debuting its B2C Sales, which will play an important role in supporting its B2B efforts with its distribution and sales partner, Batory Foods.

These results underly the efforts made over the past 6 months to build best in class, scalable E-commerce, and marketing capabilities. To support its sales efforts in Israel and the US, the Company is hiring additional key personnel, including a Head of Marketing and Business Development in the US, and is preparing to enter the market with its VINIA® proposition. Major progress has also been achieved on the North American B2B approach. The Company has been working closely with Batory Foods since the announcement of its partnership 8 weeks ago. It has finalized a Top 30 list of Major Food, Beverage, and Nutraceutical customers of Batory Foods that it will now begin targeting for VINIA® to be included as a functional ingredient in their products.

"I am really proud of the work of the team and best in class capabilities we are building in marketing VINIA® to consumers. I am elated today to share details of the early results which further reflect our ability to operationalize our Company Growth Strategy," said Ilan Sobel the CEO of the Company. "The approach we have taken in testing our sales and marketing strategies in Israel, to be followed by our entry into the US market, should prove to be effective. We are continuously learning from our experience in Israel and improving upon it. This would, we believe, allow us to build a sizeable and profitable business in Israel and most importantly, optimize our efforts and costs in the US in 2021, where we believe we can achieve significant revenues. Furthermore, we are confident we can bring the Superfruit Nutraceuticals vertical of our business into positive cash flow territory relatively quickly. I look forward to discussing the results in more detail for those attending the Webinar on Thursday at 2:00 pm Eastern Time."

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company's technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit:

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186


Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance that we will achieve our objective of making our products available in multiple markets and exposing our technology to different verticals. There is no assurance that market demand in the US will be the same as Israel or that the Israeli sales numbers will translate proportionately to the US market or that the company will achieve significant revenues in the US.There is no assurance that we will be able to sell our products to the pharmaceutical industry. There is also no assurance the Company will generate significant revenue in the global nutraceutical and dietary supplements markets. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.Revenue numbers in this press release do not reflect financial statement numbers which include a 10% reserve for possible returns under the Company's 90 days money back guarantee.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit

News Provided by Newsfile via QuoteMedia


BioHarvest Sciences

Keep reading...Show less

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the receipt of merger control clearance from the Federal Cartel Office of Germany ("FCO"), in connection with the previously announced offer (the "Offer") to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1 billion. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, 2022, and the FCO clearance was received on August 15, 2022. The Offer expired at 5:00 p.m. Eastern Time on August 15, 2022 (the "Expiration Time"), and the Offer was not extended.

This press release features multimedia. View the full release here:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead to Acquire Remaining Worldwide Rights of Trodelvy®

Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy ® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study

Trodelvy is the First TROP-2 Directed ADC to Show a Significant Improvement in Overall Survival in HR+HER2- Breast Cancer –

Planned Second Interim Analysis Demonstrated a Statistically Significant and Clinically Meaningful Benefit for Overall Survival

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Launch of New Investor Relations Website

The Gummy Project Announces Launch of New Investor Relations Website

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company")  is pleased to announce the launch of its new investor relations website at https:shopgummies.compagesinvestors.

The investor relations website features excellent functionality and streamlined access to essential investor information, including recent company press releases, sector information and more.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
bowl with healthy food on it alongside an avocado and cutlery

Hungry for Change: Investing in the Plant-based Food Industry

Animal agriculture is one of the top five sources of greenhouse gas emissions, much of which is directly attributable to livestock. It's been estimated by the United Nations, for instance, that the livestock sector represents approximately 14.5 percent of all global greenhouse gas emissions. Given the current international push for sustainability, this is a problem — and people are demanding a solution.

Driven by concerns about health, climate change and animal welfare, consumers are demandingethical and sustainable alternatives to meat, dairy, fish, and poultry. Nearly two-thirds (63 percent) of respondents to a survey on flexitarian diets would swap to plant-based alternatives because they're more ethical.

Unsurprisingly, this demand represents a considerable opportunity for anyone interested in sustainable investing. According to Bloomberg Intelligence, the global plant-based food market is expected to reach a total value of US$162 billion by 2030. A survey from the Food Institute shows that 79 percent of Americans from Generation Z choose meatless options at least once or twice a week.

Keep reading...Show less

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration ("FDA") and received scientific advice from the European Medicines Agency ("EMA") to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 -

- Ended second quarter 2022 with approximately US$384.6 million in pro-forma cash, cash equivalents and short-term investments, including net proceeds from the July 2022 financing; Cash runway extended to 2H 2025 and through the topline results of both CALM-1 and CALM-2 trials -

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News